Please assess the completion status of the following clinical trial:

Trial Title: A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* be at least 18 years old~* be willing and able to avoid all disallowed medications and contact lenses~* must have a pregnancy test if of childbearing potential~* must be able to read an eye chart from 10 feet away~Key Exclusion Criteria:~* must not have any allergies to the study medications~* must not have any ocular or non ocular condition that investigator feels will interfere with study parameters~* must not have used immunotherapy in the last 2 years~* must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bilastine 0.2% (Type: EXPERIMENTAL): Bilastine Ophthalmic solution 0.2%~1 drop in each eye at 3 separate times during a 25 day period.
- Bilastine 0.4% (Type: EXPERIMENTAL): Bilastine Ophthalmic solution 0.4%~1 drop in each eye at 3 separate times during a 25 day period.
- Bilastine 0.6% (Type: EXPERIMENTAL): Bilastine Ophthalmic solution 0.6%~1 drop in each eye at 3 separate times during a 25 day period.
- Bilastine 0% (Type: PLACEBO_COMPARATOR): Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 3 separate times during a 25 day period.

Based on this trial design, predict the completion outcome and termination type (if applicable).